The Swiss pharma company also raised its full-year guidance, with sales expected to grow by high-single digits and core ...

Ad hoc announcement pursuant to Art. 53 LR Net sales grew +15% (cc1, +12% USD) with core operating income1 up +27% (cc, +23% USD) Sales growth driven by continued strong performance from Entresto ...

Swiss pharmaceutical firm Novartis on Tuesday reported better-than-expected first-quarter sales and raised its full-year ...

FDA granted an accelerated approval for Vanrafia for the reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression. Vanrafia can be ...

The solid cash conversion allows Telix to internally fund organic growth and flexibility to pursue acquisitions. We expect the company to reinvest the majority of earnings into R&D. We forecast ...

On March 28, the FDA approved Imfinzi for use in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single-agent Imfinzi as adjuvant treatment after radical cystectomy, ...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

NVS' first-quarter performance has likely benefited from strong growth in Kisqali, Kesimpta, Pluvicto, Leqvio, Scemblix and ...

Radiopharmaceutical publicly funded in some provinces has fewer side effects than chemotherapy and can increase survival by ...

Last year, nearly half a million cancer patients received life-saving treatments, from a medicine, that's active ingredient ...

Novartis’ efforts to strengthen its wide portfolio by developing breakthrough treatments have made it even more formidable in this space. Kesimpta, Pluvicto, Scemblix, Kisqali, Leqvio and ...

European drugmaker Novartis (NVS), best known for blockbuster drugs like Entresto, Cosentyx, and Kesimpta, just announced a major U.S.